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Abstract
Although a signature of increased interferon (IFN-)alpha production is observed in HIV-1 infection, the response of
circulating plasmacytoid dendritic cells (PDC) to Toll-like receptor ligand stimulation is substantially impaired. This
functional PDC deficit, which we specifically observed in HIV-1 infected individuals with less than 500 CD4+ T cells/ml, is not
well understood. We provide evidence that the peripheral IFN-alpha production in HIV-1 infection is actively suppressed by
the enhanced interaction of CD40 ligand (CD40L), a member of the tumor necrosis factor family, and its receptor CD40,
which are both upregulated upon immune activation. Plasma levels of soluble CD40L were significantly higher in untreated
HIV-1 infected individuals (n=52) than in subjects on long-term antiretroviral therapy (n=62, p,0.03) and in uninfected
control donors (n=16, p,0.001). Concomitantly, cell-associated CD40L and the expression of the receptor CD40 on the PDC
were significantly upregulated in HIV-1 infection (p,0.05). Soluble and cell-associated CD40L inhibited the PDC-derived IFN-
alpha production by CpG oligodeoxynucleotides dose-dependently. This suppressive effect was observed at much lower,
physiological CD40L concentrations in peripheral blood mononuclear cells (PBMC) of HIV-1 infected individuals compared
to controls (p,0.05). The CpG-induced IFN-alpha production in PBMC of HIV-1 infected donors was directly correlated with
PDC and CD4+ T cell counts, and inversely correlated with the viral loads (p,0.001). In HIV-1 infected donors with less than
500 CD4+ T cells/ml, the CpG-induced IFN-alpha production was significantly correlated with the percentage of CD40-
expressing PDC and the level of CD40 expression on these cells (p,0.05), whereas CD40L plasma levels played a minor role.
In addition, low-dose CD40L contributed to the enhanced production of interleukin 6 and 8 in PBMC of HIV-1 infected
donors compared to controls. Our data support the conclusion that the chronic immune activation in HIV-1 infection
impairs peripheral PDC innate immune responses at least in part via enhanced CD40:CD40L interactions.
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Introduction
Evidence is accumulating from human and simian studies that
chronic immune activation with enhanced T-cell turnover and
apoptosis plays a crucial role in lentiviral pathogenesis [1]. An
important trigger of immune activation are the type I interferons
(IFN), mainly produced by plasmacytoid dendritic cells (PDC)
[2,3]. PDC express Toll-like receptors (TLR) 7 and 9 for the
recognition of single-stranded RNA and CpG-like DNA, respec-
tively. Upon stimulation, proinflammatory cytokines are secreted
that initiate early immune responses. High-titered HIV-1 and in
particular HIV-1 infected cells induce major IFN-alpha produc-
tion [4–6]. The antiviral activity, however, is counteracted by the
apoptosis of uninfected CD4+ bystander cells via enhanced
expression of the tumor necrosis factor (TNF)-related apoptosis-
inducing ligand and its death receptor 5 [7].
The signature of increased expression of IFN-stimulated genes
in peripheral cells and lymphatic tissue [8,9] faces an impaired
IFN-alpha production upon TLR stimulation in circulating
mononuclear cells and PDC of HIV-1 infected individuals [10–
14]. This reduced responsiveness to stimulation was recently
associated with prior activation of PDC via type I IFNs or virions
in vivo [15]. Another cause may be a cellular factor induced upon
immune activation. In this respect, we focused on the costimula-
tory molecule CD40 and its ligand, CD40L (CD154), because we
and others have shown that CD40L reduced the IFN-alpha
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B cells, monocytes, dendritic cells, endothelial and epithelial cells
[17]. CD40L, a member of the TNF family, is primarily expressed
on activated CD4+ T cells and on a small proportion of CD8+ T
cells and platelets [17]. The interaction of CD40 and CD40L is
important for activating antigen presenting cells, T cells and
macrophages, antibody isotype switching, and germinal center
formation. CD40L may be expressed as a heteromultimeric
complex [18]. After cleavage of the transmembrane protein by
naturally occurring metalloproteinases, the soluble form (sCD40L)
still binds to CD40 and delivers biological signals like a cytokine
[19].
In HIV-1 infection, CD40 is upregulated on myeloid and
plasmacytoid dendritic cells in the peripheral blood [20] and
lymphoid tissue [21,22]. Increased sCD40L levels are detected in
the serum of HIV-1 infected subjects and cerebrospinal fluid of
patients with AIDS dementia [23,24]. Controversial data are
reported for cell-associated CD40L (cCD40L). Enhanced expres-
sion at baseline was observed on CD4+ cells of HIV-1 infected
patients, reversed by antiretroviral therapy [25], and on platelets
[26]. In contrast, others reported comparable cCD40L levels on
resting CD4+ T cells in HIV-1 infected children and uninfected
controls [27]. Upon stimulation, CD40L was not sufficiently
upregulated on CD4+ cells of HIV-1 infected subjects, which may
result in deficient activation of dendritic cells and an ineffective
cellular immune response [28–30].
In our study, we hypothesized that the HIV-1 induced immune
stimulation is directly linked with the decreased PDC IFN-alpha
production upon stimulation. We focused on the role of CD40L
and provide evidence that physiological concentrations of this
molecule reduce the TLR-induced IFN-alpha production in HIV-
1 infection.
Materials and Methods
Ethics statement
All protocols for this study were approved by the ethical
committee of the Medical Faculty, Friedrich-Alexander-Universi-
ta ¨t Erlangen-Nu ¨rnberg (Ref. no. 3375). Ethical guidelines accord-
ing to the declaration of Helsinki were adhered to, and written
informed consent was obtained from the study participants.
Patient characteristics
The HIV-1 infected subjects (n=44) were monitored at two
specialized outpatient centers in Nu ¨rnberg and Erlangen,
Germany. None of them had received antiretroviral therapy.
Controls (n=16) were age-matched healthy volunteers at the
Institute of Virology, Erlangen, Germany (patients vs. controls,
median 41.3 vs. 41.1 years, range 25–68 vs. 25–67 years, p=0.73,
n.s.). Data of some participants were reported recently [31].
Details on baseline cell counts of HIV-1 infected patients and
controls are given in Fig. 1a. Since the study developed over time,
Figure 1. Levels of soluble and cell-associated CD40 ligand in HIV-1 infected patients (pat.) and controls (ctrl.). (a) Baseline counts of
natural killer (NK) cells, monocytes, CD4+ and CD8+ T cells, B cells, plasmacytoid (PDC) and myeloid dendritic cells (MDC) in HIV-1 infected individuals
and uninfected controls, given as percentages (%) of peripheral blood mononuclear cells (PBMC). (b) Plasma levels of interleukin (IL-)3 and soluble
CD40 ligand (sCD40L), the latter also analyzed in patients on antiretroviral therapy (HAART). (c) Expression of cell-associated CD40L (cCD40L) and (d)
CD40 at the cell surface, evaluated by flow cytometry as percentage of positive cells and delta mean fluorescence intensity after subtraction of
isotype controls. Data are presented as median, interquartile ranges (boxes), and 10% and 90% values (whiskers). *p,0.05, **p,0.01, ***p,0.001
(Mann-Whitney test).
doi:10.1371/journal.pone.0033925.g001
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repeated later on, because antiretroviral therapy was initiated.
However, all values that were obtained are reported.
Isolation and stimulation of cells
EDTA-anticoagulated blood was processed within a few hours
(h). PBMC were isolated using Ficoll (Biochrom AG, Berlin,
Germany) density gradient centrifugation, and plated at 10
6 cells/
500 ml in 24-well flat bottom plates. Viability of cells was checked
by trypan blue staining. PBMC were cultivated in RPMI 1640
media (Gibco, Eggenstein, Germany) plus 10% heat-inactivated
fetal calf serum (FCS) (Lonza, Basel, Suisse), 50 mg/ml glutamine,
200 U/ml penicillin, and 90 U/ml streptomycin. IL-3 (R&D
Systems, Wiesbaden-Nordenstadt, Germany) was added at
indicated concentrations. Cells were stimulated directly after
isolation. Supernatants were harvested and stored at 220uC. For
the induction of CD40L, cells were stimulated with 1 mg/ml
ionomycin und 10 ng/ml PMA (both Sigma-Aldrich) [32]. CD4+
and CD8+ T cells as well as PDC were purified from PBMC by
positive selection (Miltenyi Biotec, Bergisch-Gladbach, Germany).
Determination of cytokines
Cell culture supernatants were analyzed using an IFN-alpha 2a/
2b ELISA module set (Bender MedSystems, Vienna, Austria).
Samples were measured within the linear range of the assay. IL-3
and sCD40L concentrations were determined using the Quanti-
kine Immunoassay human IL-3 (R&D Systems) and the human
sCD40L module set (Bender Medsystems), respectively. Other
cytokines were measured using the FlowCytomix technology
(Bender MedSystems).
Generation of the viral stock
The X4-tropic primary virus isolate HIV-1SF33 was grown on
PHA-stimulated CD4+ T cells. At peak viral replication,
supernatants were transferred to PHA-stimulated PBMC. Super-
natants were filtered through 0.22 mm filter devices (Millipore,
Schwalbach, Germany), aliquoted and stored at 280uC. The
TCID50 was quantified in PHA- and IL-2-stimulated PBMC [33].
Cell lines
CD40L-expressing BHK and control cells [34] were grown in
Dulbecco’s modified Eagles medium (DMEM) (Gibco), supple-
mented with 10% FCS and antibiotics (see above). For the
production of sCD40L-containing or control supernatants, BHK
cells were grown to subconfluency, washed twice with DPBS, and
fed with serum-free DMEM. After 24 h, supernatants were
harvested and concentrated 100-fold using the Centricon Plus-
70-10 Centrifugal Filter devices (Millipore). Aliquots were stored at
280uC. To determine the effects of cCD40L, BHK cells were
plated at different concentrations into 24-well flat bottom plates.
The next day, the plates were incubated on ice for a few minutes.
Cells were harvested, washed and fixed in 1.5 ml cryotubes
(Eppendorf, Hamburg, Germany) using 4% PFA in DPBS, washed
again six times in DPBS, and then added to the PBMC.
Biologic reagents
Cell-culture grade sCD40L and the respective CD40L antibody
were obtained from R&D Systems. Endotoxin-free CpG-A (ODN
6016, 59-T*C-G-A-C-G-T-C-G-T-G-G*G*G*G-39, *indicates
phosphorothioate and – phosphodiester bonds) and CpG-P
(ODN 21798, 59-T*C-G*T*C-G*A*C-G*A*T*C-G*G*C*G*C-
G*C*G*C*C*G-39) were provided by the Pfizer Oligonucleotide
Therapeutics Unit – Coley Pharmaceutical GmbH (Du ¨sseldorf,
Germany) and used at 0.75 mM and 0.25 mM, respectively. The
synthetic TLR7 agonist S-27609, kindly provided by Richard
Miller, 3M Pharmaceuticals (St. Paul, UK), was used at 5 mM.
Western Blotting
The SDS-denatured sCD40L preparations were separated on a
10% polyacrylamide gel, transferred to a PVDF membrane,
incubated with anti-CD40L over night, and then a secondary
horseradish peroxidase-conjugated antibody (Dako, Hamburg,
Germany; 1:1,000). The protein size was assessed using the Page
Ruler Prestained Protein Ladder (Fermentas, St. Leon-Rot,
Germany). Luminescence was developed by adding ECL solution
containing luminol (Sigma-Aldrich, Taufkirchen, Germany),
documented using the Fujifilm LAS-1000 plus gel documentation
system.
FACS analysis
Isolated PBMC were washed with DPBS supplemented with 1%
FCS and 0.5 mM EDTA (Sigma-Aldrich). FcR-blocking reagent
(Miltenyi Biotec) was added at 4uC for 10 minutes (min) to reduce
unspecific staining. PDC and myeloid dendritic cells were stained
using a cocktail of PE-conjugated lineage antibodies (CD3, CD14,
CD16, and CD20; Immunotools, Friesoythe, Germany), PE-Cy5-
conjugated anti-CD11c, and PE-Cy7-conjugated anti-CD4 (both
BD Bioscience, Heidelberg, Germany). B cells were identified
using PE-Cy5 conjugated anti-CD19 and APC-conjugated anti-
CD20 (Immunotools). CD4+ and CD8+ T-lymphocytes, mono-
cytes, and natural killer (NK) cells were stained using a cocktail of
PE-conjugated anti-CD16 (BD Bioscience), PE-Cy5-conjugated
anti-CD14 (Immunotools), Pacific Blue-conjugated anti-CD3, PE-
Cy7-conjugated anti-CD4 (BD Bioscience) and APC-conjugated
anti-CD8 (Immunotools). CD40 and CD40L (CD154) were
stained using FITC-conjugated antibodies (eBioscience, Frankfurt,
Germany). CD4+ T cell memory subsets were identified using
CD3-PB and CD4-PE-Cy7 (both BD Bioscience) in addition to
CD45RO-APC and CD197(CCR7)-PE (both eBioscience). Re-
spective mouse IgG antibodies served as isotype controls. After
staining at 4uC for 20 min, cells were washed and fixed in 4%
paraformaldehyde (Sigma-Aldrich, Taufkirchen). Depending on
the expected cell frequency, a total of 100,000–400,000 events
were collected using a four-color FACS Calibur with CellQuest
3.3 software (BD Biosciences). CD4+ T cell memory subsets were
dissected using an LSR II. The data were analyzed using FCS
Express V3.
Statistics
The Mann-Whitney U-test was used for comparisons between
patients and controls. Independently repeated experiments were
compared using the paired and unpaired Student’s t-test. All
statistical calculations assumed a two-sided significance at p values
, 0.05.
Results
Patient characteristics
We studied 52 untreated HIV-1 infected subjects (48 male, 4
female). All males except two were infected through sex with men.
The participants were classified into CDC categories A1 (n=16),
A2 (n=20), A3 (n=2), B1 (n=4), B2 (n=6), B3 (n=1), C2 (n=1),
and C3 (n=2). AIDS-defining illnesses were pneumocystis
pneumonia (n=1), chronic diarrhea and wasting (n=1), candida
oesophagitis (n=1), and HIV-1 associated encephalopathy (n=2).
Eight patients suffered from chronic bronchitis and/or allergic
coryza, four from lues, two from chronic hepatitis, and one each
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recurrent herpes genitalis, condylomata accuminata, nephro-
pathia, and pancreatitis. Two patients were diabetic; one
hemophiliac, one addicted to illegal drugs, and three addicted to
alcohol. The median CD4+ T cell count was 397/ml (interquartile
range, IQR, 273–627; range, 19–1780), the median viral load 4.4
log10 (IQR, 3.9–5.1 log10; range, 1.3–5.8 log10). Baseline
percentages of the different cell types are included in Fig. 1a.
TLR-ligand induced IFN-alpha production is decreased in
HIV-1 infection
The function of PDC was investigated using the oligodeox-
ynucleotides (ODN) CpG-A (6016) and CpG-P (21798) [35] as
TLR9 stimuli (Fig. 2). PBMC of HIV-1 infected patients secreted
significantly less IFN-alpha than controls upon stimulation with
both CpG ODN (p,0.001). When the patients were divided into
three groups according to their CD4+ T cell counts, it became
obvious that only patients with less than 500 CD4+ T cells/ml
contributed to this difference (p,0.01). When the CpG-induced
IFN-alpha production was corrected for the percentage of PDC,
PBMC of HIV-1 infected patients with CD4+ T cell counts below
500/ml still produced significantly less IFN-alpha compared to
controls (p,0.05), whereas for HIV-1 infected patients with more
than 500 CD4+ T cells/ml, the normalized IFN-alpha production
was not significantly different from control donors. Thus, the
functional response of circulating PDC to TLR9 stimulation was
Figure 2. Deficits in interferon (IFN) alpha production in HIV-1 infected patients (pat.) versus control donors (ctrl.). Peripheral blood
mononuclear cells (PBMC) were exposed to (a) the CpG-A oligonucleotide 6016 (0.75 mM) and (b) the CpG-P oligodeoxynucleotide 21798 (0.25 mM)
for 20 hours (h). The IFN-alpha production is given before and after normalization for the percentage of plasmacytoid dendritic cells (PDC). The data
of HIV-1 infected patients were also analyzed for samples with CD4+ T cell counts below 250/ml( ,250), between 250–500/ml (250–500), and above
500/ml( .500). Data are presented as median, interquartile ranges (boxes), and 10% and 90% values (whiskers). *p,0.05, **p,0.01, ***p,0.001
(Mann-Whitney test). Part of the data were presented in another study [31]. Similar data were obtained using S-27609 (data not shown).
doi:10.1371/journal.pone.0033925.g002
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500 CD4+ T cells/ml. The response of PBMC to stimulation with
the TLR7 agonist S-27609 was also significantly lower in HIV-1
infected patients compared to controls, before and after correction
for the percentage of PDC (both p,0.05; data not shown). In
conclusion, both TLR7 and TLR9 responses are impaired in
HIV-1 infection.
sCD40L and cCD40L are significantly elevated in HIV-1
infection
In the search for a cellular factor which is upregulated upon
immune activation and suppresses IFN-alpha production, we
investigated two molecules: IL-3, secreted by activated CD8+ T
cells, which plays an important role in PDC survival and
maturation [36]; and CD40L, mainly produced by activated
CD4+ T cells, which inhibits the PDC-derived IFN-alpha
production at high concentrations [5,16]. IL-3 plasma levels were
similar in HIV-1 infected subjects (n=15) and controls (n=10)
(median, 6.0 vs. 7.4 pg/ml; IQR 3.4–15.5 pg/ml vs. 1.0–31.0 pg/
ml, respectively) (p=0.89, n.s.) (Fig. 1b). The sCD40L plasma
levels, however, were significantly elevated in HIV-1 infected
patients (n=52) compared to controls (n=16) (median, 7.9 vs.
3.7 ng/ml; IQR 5.3–10.3 ng/ml vs. 2.0–5.7 ng/ml, respectively)
(p,0.001) (Fig. 1b). These data compare to 2-fold increased
Figure 3. Suppression of interferon (IFN) alpha production by CD40 ligand. (a) Preincubation of peripheral blood mononuclear cells (PBMC)
of controls without (w/o) or with (w/t) a cell-culture grade commercial soluble CD40 ligand (sCD40L; 3 mg/ml) for 48 hours (h), followed by
stimulation with CpG-P 21798. Data represent 11 and 5 separate experiments for IL-3 levels of 0 and 5–5,000 pg/ml, respectively. The arrow indicates
physiological IL-3 levels. (b) Neutralization of sCD40L with a cell-culture grade anti-CD40L antibody with subsequent CpG-P stimulation in two
donors. Similar data were obtained using CpG-A (data not shown). (c) Direct effect of sCD40L (3 mg/ml) on the CpG-P induced IFN-alpha production
by plasmacytoid dendritic cells (PDC) of control donors. (d) Expression of cell-associated CD40L (cCD40L) on baby hamster kidney (BHK) cells. (e)
Shedding of sCD40L into the cell culture supernatants after 24 h and 48 h of culture. (f) Western Blot of concentrated supernatants of CD40L-
expressing BHK cells and a commercial sCD40L preparation (R&D Systems) using reducing conditions. Data represent three separate experiments. No
bands were detected in the supernatants of BHK wild type cells (data not shown). (g) Inhibition of CpG-P induced IFN-alpha production using sCD40L
from R&D Systems and BHK cells. Statistics were calculated between PBMC of HIV-1 infected patients (pat.) (n=5) and controls (ctrl.) (n=10) exposed
to sCD40L (R&D Systems). (h) cCD40L expression on CD4+ and CD8+ T cells of control donors after stimulation with mock (grey filled curve) or PMA/
ionomycin (black dotted curve). (i) Inhibition of CpG-P induced IFN-alpha production by increasing counts of untreated (unstim.) or PMA/ionomycin-
stimulated (stim.) CD4+ T cells, which were left unfixed or fixed used 4% paraformaldehyde, and coincubated with 1610
6 PBMC of five control
donors. Similar results were obtained with CpG-A (data not shown). (j) Inhibition of CpG-P induced IFN-alpha production by paraformaldehyde-fixed
cCD40L-expressing and wild type (WT) BHK cells using PBMC of eight control donors. Data are presented as mean and standard error. *p,0.05,
**p,0.01, ***p,0.001 (Student’s t-test).
doi:10.1371/journal.pone.0033925.g003
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Similarly, cCD40L was significantly upregulated on monocytes,
CD4+ T cells, B cells, and a minority of CD8+ T cells in HIV-1
infected subjects (n=37) compared to controls (n=16) (p,0.05)
(Fig. 1c). Since sCD40L and cCD40L bind to CD40, we studied
the expression of CD40 on PDC. As demonstrated by others [20],
CD40 was upregulated on the PDC of HIV-1 infected patients
(n=37) compared to controls (n=16) (p,0.05) (Fig. 1d). Notably,
ligand and receptor were concomitantly upregulated in HIV-1
infection.
sCD40L plasma levels are decreased upon antiretroviral
treatment
To address the effect of antiretroviral therapy, we analyzed
sCD40L plasma levels in a total of 62 HIV-1 infected subjects with
undetectable viral loads for at least one year after initiation of
antiretroviral therapy. These samples had been sent to the
diagnostic services of the Institute of Virology, Erlangen, for
routine viral load monitoring. The mean time with viral loads
below detection level was 65623 months (range, 13–95 months).
The sCD40L plasma levels were significantly decreased in
HAART-treated vs. therapy-naı ¨ve patients (p=0.03), indicating
a decrease of immune stimulation with antiretroviral therapy
(Fig. 1b). However, the sCD40L plasma levels in HAART-treated
patients were still significantly higher than in uninfected controls
(p=0.03).
sCD40L suppresses the PDC-derived IFN-alpha
production
The effect of sCD40L on the IFN-alpha induction was
investigated by preincubation of control PBMC with a cell-culture
grade commercial sCD40L (3 mg/ml) for 48 h and subsequent
exposure to CpG-P. The IFN-alpha production was significantly
reduced by 2–3-fold (p,0.05) at physiological IL-3 levels (5–
10 pg/ml) and over a broad range of IL-3 concentrations (5–
5,000 pg/ml). (Fig. 3a). This did not occur in the absence of IL-3,
likely because this cytokine contributes to PDC survival over the
three days of incubation [36]. To mimic physiological conditions
as close as possible, further experiments were performed using IL-
3 concentrations of 5–10 pg/ml. The specificity of the suppressive
effect of sCD40L on the IFN-alpha production was proven by
neutralization with a respective cell culture-grade antibody
(Fig. 3b). The inhibitory effect of sCD40L was also observed
with purified PDC (Fig. 3c), providing evidence for a direct
suppressive effect of sCD40L on the PDC-derived IFN-alpha
production.
The effect of sCD40L occurs at physiological levels in HIV-
1 infection
The inhibitory effect of the commercial sCD40L was corrob-
orated using a more natural source of this protein. Stably
transfected baby hamster kidney (BHK) cells [34] expressed
cCD40L at the surface (Fig. 3d) and released sCD40L into the
cell culture supernatants (Fig. 3e). These fluids were concentrated
using centrifugal filter devices. sCD40L is a 18 kDa protein,
forming trimers [19]. Western blotting showed sCD40L mono-
mers and multimers in the commercial and the BHK-derived
preparations (Fig. 3f), which were used to titrate the inhibitory
effect of sCD40L on the IFN-alpha production in control PBMC.
The suppressive effects of both sCD40L preparations were similar
with a 50% inhibitory concentration (IC50) in the range of 500 ng/
ml (Fig. 3g). This IC50 was considerably above physiological
sCD40L levels in control donors (,50-fold) (Fig. 1b). Considering
that not only CD40L, but also the receptor CD40 was upregulated
on the PDC of HIV-1 infected subjects (Fig. 1d), we performed
similar experiments using PBMC of these donors. The respon-
siveness to sCD40L was now substantially increased, the IC50
(10 ng/ml) being within sCD40L plasma levels in HIV-1 infected
individuals (Fig. 3g). Thus, PDC of these subjects in contrast to
uninfected donors are susceptible to low physiologic levels of
sCD40L.
Inhibitory effect of cCD40L on the IFN-alpha production
To investigate whether cCD40L also suppressed the IFN-alpha
production, CD4+ and CD8+ T cells were stimulated with PMA/
ionomycin for 3–4 h. Upon stimulation, cCD40L was upregulated
on all CD4+ T cells and on a subset of CD8+ T cells (Fig. 3h). In
parallel, CD4 was downregulated and CCR7 was upregulated on
CD4+ T cells (Fig. S1). When CD4+ T cell subsets were
compared, central memory CD45RO+ CCR7+ cells upregulated
cCD40L comparably to CD45RO2 CD4+ T cells, whereas
CD45RO+ CCR72 effector memory cells expressed tenfold less
cCD40L (Fig. S1). Mock- and PMA/ionomycin-stimulated CD4+
T cells were washed, fixed with 4% paraformaldehyde to prevent
shedding of CD40L, and coincubated with PBMC of control
donors for 2d prior to CpG-P stimulation. The strongest
suppressive effects on the IFN-alpha induction were observed
with unfixed PMA/ionomycin-stimulated CD4+ T cells (Fig. 3i).
This effect was seen with as low as 500–5000 CD4+ T cells in 10
6
PBMC (1:2000). Minor effects were observed with fixed PMA/
ionomycin-stimulated CD4+ T cells, which no longer shed
sCD40L. However, these cells still suppressed more than fixed
and unfixed unstimulated cells. To reduce the suppressive effect to
cCD40L, fixed CD40L-expressing and wild type BHK cells were
coincubated with control PBMC. The IFN-alpha production was
reduced with high numbers of CD40L-expressing but not wild
Figure 4. Effect of CD40L neutralization on the suppression of
CpG-P induced interferon (IFN)-alpha production. Peripheral
blood mononuclear cells (PBMC) of three control donors were
preincubated with 50,000 unstimulated (unstim.) or PMA/ionomycin-
stimulated (stim.) CD4+ T cells of the respective donors for 48 hours, in
the absence or presence of a cell-culture grade anti-CD40L antibody
(30 mg/ml), and then stimulated with CpG-P 21798 (0.25 mM) for
additional 24 hours. Data are presented as mean and standard error.
*p,0.05, **p,0.01 (Tukey HSD test).
doi:10.1371/journal.pone.0033925.g004
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in suppressing IFN-alpha production.
Immune activation suppresses IFN-alpha production at
least in part by CD40L
So far, we have shown that CD40L suppresses IFN-alpha
production. In a next step, we wanted to evaluate the magnitude of
the CD40L effect in immune activation. For this purpose, PBMC
of three controls donors were preincubated with 50,000 unfixed
PMA/ionomycin-stimulated CD4+ T cells with and without the
neutralizing CD40L antibody, and then stimulated with CpG-P.
The antibody reversed the suppressive effect of PMA/ionomycin-
stimulated CD4+ T cells on the IFN-alpha production partially
(p,0.05), but not completely (Fig. 4). In conclusion, CD40L is an
important factor in the immune activation that contributes to the
suppression of IFN-alpha production. However, additional factors
appear to be involved in this process.
HIV-1 does not promote shedding of CD40L
To investigate whether HIV-1 infection contributes to shedding
of CD40L from the cell surface, PBMC, CD4+ and CD8+ T cells
were stimulated with PHA for 3 d, and then infected with HIV-
1SF33 at a high MOI (0.1) for 2 d. After PMA/ionomycin
stimulation, sCD40L was measured in the cell culture superna-
tants. The majority of sCD40L was detected in the supernatants of
CD4+ T cells 4–6 h post stimulation (Fig. S2). HIV-1 infection
did not contribute to shedding of CD40L under these conditions.
IFN-alpha production correlates with clinical parameters
in HIV-1 infection
Next, we studied the influence of PDC and CD4+ T cell counts
and viral loads in HIV-1 infected subjects on the CpG-induced
IFN-alpha production in PBMC of these donors. The IFN-alpha
production was directly correlated with the PDC percentage
(Fig. 5a) and the CD4+ T cell count (Fig. 5b), and inversely
correlated with the viral load (Fig. 5c) (all p,0.001). Similar data
were obtained when the analyses were limited to patients with less
than 500 CD4+ T cells/ml (all p,0.001). Thus, all three
parameters affect the PDC-derived IFN-alpha production.
The functional PDC deficit correlates with the expression
of CD40 on the PDC in HIV-1 infected subjects with
reduced CD4+ T cell counts
Did sCD40L also affect the CpG-induced IFN-alpha produc-
tion in HIV-1 infected donors? The sCD40L plasma levels were
significantly correlated with the CD4+ T cell counts (rs=0.31,
p=0.03), as similarly reported by others [23], but not with the
percentage of PDC (rs=0.24, p=0.09, n.s.) nor the viral loads
Figure 5. Correlation of CpG-induced interferon (IFN)-alpha production with clinical parameters. Spearman rank order correlation of
CpG-A and CpG-P induced IFN-alpha production with (a) the percentage of PDC, (b) the CD4+ T cell count, and (c) the viral load in untreated HIV-1
infected individuals (n=40).
doi:10.1371/journal.pone.0033925.g005
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correlated with the CpG-induced IFN-alpha production, neither
for all HIV-1 infected patients nor those with less than 500 CD4+
T cells/ml( p .0.05, n.s.) (Table 1). Similar data were obtained
when the IFN-alpha induction was normalized for the percentage
of PDC (p.0.05, n.s.). Thus, higher sCD40L levels could not
explain the functional PDC deficit in HIV-1 infection.
Next, we addressed the role of the increased expression of CD40
on the PDC in HIV-1 infected individuals. Neither the mean
fluorescence intensity nor the percentage of CD40-expressing
PDC were correlated with CD4+ T cell counts, PDC percentages,
or viral loads, irrespective of whether all HIV-1 infected subjects
or those with less than 500 CD4+ T cells/ml were analyzed
(p.0.05, n.s.). In contrast, sCD40L plasma levels were signifi-
cantly correlated with the percentage of CD40-expressing PDC
(rs=0.34, p=0.04) and the mean fluorescence intensity (rs=0.40,
p=0.02) in all HIV-1 infected subjects and in patients with less
than 500 CD4+ T cells/ml( r s=0.43, p=0.04, and rs=0.56,
p=0.008, respectively). Notably, also the CpG-induced IFN-alpha
production was significantly correlated with the expression of
CD40 on PDC, when the analysis was limited to patients with less
than 500 CD4+ T cells/ml( Table 1). In conclusion, enhanced
CD40:CD40L interactions play a role for the functional PDC
deficit in HIV-1 infected subjects with low CD4+ T cell counts.
sCD40L modifies the cytokine profile in HIV-1 infection
The effects of sCD40L on the cytokine production were
determined in PBMC of HIV-infected (n=5) and control donors
(n=4) using a fluorescent bead immunoassay (Fig. 6). A low
concentration of sCD40L (50 ng/ml) significantly upregulated IL-
8 in the PBMC of HIV-infected subjects (p,0.05). A similar effect
was observed after CpG-P stimulation, whereas PBMC of control
donors upregulated IFN-gamma, TNF-alpha, and IL-10. Com-
bined stimulation with sCD40L and CpG-P significantly upregu-
lated IL-6 in PBMC of HIV-infected subjects (p,0.05), indicating
that low-dose CD40L causes a shift in the cytokine profile.
Discussion
Our study shows, for the first time, that the upregulation of
CD40L and in particular the receptor CD40 on the surface of
PDC contributes to reduction of the PDC-derived IFN-alpha
production in HIV-1 infection. The sCD40L plasma levels, the
expression of cCD40L on several cell populations and the
expression of CD40 on the PDC were concomitantly upregulated
in HIV-1 infected subjects (Fig. 1), which corroborates data by
other groups [20–24]. In vitro, sCD40L obtained from two different
sources and cCD40L specifically and dose-dependently reduced
the CpG-induced IFN-alpha production (Fig. 3). With PBMC of
uninfected control donors, the suppressive effect was observed at
high sCD40L concentrations only; in contrast, ,50-fold lower
concentrations were sufficient when PBMC of HIV-1 infected
subjects were used (Fig. 3d). These findings suggest that the
concomitant upregulation of CD40L and in particular its receptor
on the PDC becomes physiologically relevant. The in vivo data
support this conclusion; not sCD40L plasma levels, but the
enhanced expression of CD40 was significantly correlated with the
CpG-induced IFN-alpha production in PBMC of HIV-1 infected
donors (Table 1). This effect was limited to subjects with less than
500 CD4+ T cells/ml, which remarkably correlated with the fact
that the functional PDC deficit was most evident in these donors
(Fig. 2).
The CpG-induced IFN-alpha production in PBMC of HIV-1
infected subjects was also substantially affected by PDC and CD4+
T cell counts and viral loads (Fig. 4), suggesting that the
progression of disease negatively impacts PDC functions. PDC and
CD4+ T cell counts recover at least partially in subjects on
antiretroviral therapy [37,38]. Therefore, it was interesting to
investigate sCD40L plasma levels in HAART-treated patients.
Sipsas et al. reported that sCD40L plasma levels were correlated
with CD4+ T cell counts, and that both markers increased in
parallel after 8–12 months of antiretroviral therapy [23]. In
contrast, Sousa et al. observed a decline of cCD40L expression on
Table 1. Correlation of the CpG-induced interferon (IFN) alpha production with sCD40L plasma levels and the expression of CD40
on the PDC in HIV-1 infected subjects.
HIV-1 infected subjects
(n=40)
HIV-1 infected subjects with ,500/ml
CD4+ T cells (n=25)
Parameter Stimulus Readout r(s) P r(s) P
sCD40L plasma levels (ng/ml) CpG-A IFN-alpha (pg/ml) 0.05 0.76 (n.s.) 20.30 0.15 (n.s.)
IFN-alpha (pg/ml)/PDC (%) 20.25 0.12 (n.s.) 20.25 0.22 (n.s.)
CpG-P IFN-alpha (pg/ml) 0.11 0.22 (n.s.) 20.21 0.32 (n.s.)
IFN-alpha (pg/ml)/PDC (%) 0.12 0.48 (n.s.) 20.07 0.72 (n.s.)
HIV-1 infected subjects
(n=25)
HIV-1 infected subjects with ,500/ml
CD4+ T cells (n=15)
CD40 expression on PDC (MFI) CpG-A IFN-alpha (pg/ml) 20.27 0.21 (n.s.) 20.59 0.03
CpG-A IFN-alpha (pg/ml)/PDC (%) 20.32 0.13 (n.s.) 20.36 0.21 (n.s.)
CpG-P IFN-alpha (pg/ml) 20.22 0.31 (n.s.) 20.70 0.005
CpG-P IFN-alpha (pg/ml)/PDC (%) 20.45 0.03 20.70 0.005
CD40 expression (% PDC positive) CpG-A IFN-alpha (pg/ml) 20.17 0.42 (n.s.) 20.58 0.02
CpG-A IFN-alpha (pg/ml)/PDC (%) 20.40 0.05 20.69 0.004
CpG-P IFN-alpha (pg/ml) 20.13 0.55 (n.s.) 20.37 0.17 (n.s.)
CpG-P IFN-alpha (pg/ml)/PDC (%) 20.10 0.64 (n.s.) 20.50 0.05
r(s)=Spearman rank correlation coefficient, MFI mean fluorescence intensity, n.s. not significant.
doi:10.1371/journal.pone.0033925.t001
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reported a reduced CD40 expression on the PDC of treated HIV-1
infected subjects [20]. We confirmed that sCD40L plasma levels
were significantly correlated with the CD4+ T cell counts in our
study participants (p=0.03). In addition, we observed a transient
increaseofsCD40Lplasma levelsinmost subjectsaftertheinitiation
of antiretroviral therapy (Fig. S3). Notably, this kinetics was
delayed in patients with less than 250 CD4+ T cells/ml, most likely
reflecting the slower increase of CD4+ T cells in these donors.
However, sCD40L plasma levels were significantly lower in patients
on long-term antiretroviral treatment compared to untreated
subjects (p=0.03) (Fig. 1b), probably reflecting a decrease of
immune activation over time. Still, sCD40L plasma levels were
higher than in uninfected controls, suggesting that chronic immune
activation is not completely resolved by antiretroviral therapy.
The CD40:CD40L interaction is known to be important for
activating antigen presenting cells, T cells and macrophages,
antibody isotype switching, and germinal center formation [17]. In
this respect, the reduction of IFN-alpha production by CD40L
may be a physiological reaction, namely to limit the antiprolifer-
ative effect of IFN-alpha when antigen-specific CD4+ T cells
expand. These adaptive immune responses usually result in the
elimination of the pathogen. In HIV-1 infection, however, the
virus cannot be eliminated and thus propagates continuous
immune activation concomitant with a CD4+ T cell decline.
Notably, the suppressive effect of PMA/ionomycin-stimulated
CD4+ T cells on the IFN-alpha production was not completely
reversed by the neutralizing antibody to CD40L (Fig. 4),
suggesting that others factors besides CD40L contribute to
silencing of PDC innate responses.
Recently, the reduced responsiveness of PDC to stimulation was
associated with prior activation of these cells via IFN-alpha or
HIV-1 particles in vivo [15]. A signature of increased IFN-alpha
production has been observed in peripheral cells and in particular
in the lymphatic tissue, which obviously contributes to the
immunopathogenesis of HIV-1 infection [7–9,39]. How does this
reconcile with our data of reduced IFN-alpha production upon
enhanced CD40:CD40L interactions? CD40L-expressing CD4+
T cells are present in the periphery and in the lymphatic tissue,
corroborated by the enhanced expression of CCR7 of central
memory CD4+ T cells upon immune activation (Fig. S1),
supporting depletion of these cells from the peripheral blood and
homing to lymphatic tissue [40]. Importantly, PDC of HIV-1
infected donors can still be activated by strong stimuli, e.g. CpG-
ODN or TLR7 agonists, and produce IFN-alpha, although at a
lower level than uninfected controls [13,31,41]. In this respect,
HIV-1 infected cells are a robust stimulus of IFN-alpha production
[6,42], whereas virions are only effective at high titer [4,5,7],
which we confirmed (Fig. S4). Therefore, we propose a model
with an increased IFN-alpha production mainly in the lymphatic
tissue, induced by cell:cell contact of PDC with HIV-1 infected
CD4+ T cells, whereas the suppressive effect of sCD40L on PDC
innate immune responses predominates in the periphery [43].
Along this line, we did not observe increased IFN-alpha levels in
the peripheral blood of our study participants (data not shown),
which is consistent with a recent report showing comparable IFN-
alpha levels in the plasma of aviremic and viremic HIV-1 infected
subjects and controls [44]. However, PDC homed to lymphatic
tissue should be considered an important source of IFN-alpha.
Thus, the imbalanced release of IFN-alpha appears to be crucial
for the immunopathogenesis of HIV-1 infection.
The reduced IFN-alpha production in the periphery of HIV-1
infected individuals may compromise the long-term immune
control of viral infections and associated tumors, which are in
principle susceptible to type I IFN. In this respect, HHV-8-
associated Kaposi sarcoma is observed in patients with preserved
CD4+ T cell counts; the prevalence of papillomavirus-related anal
neoplasia continues to increase in aging HIV-1 infected individuals
despite highly active antiretroviral therapy [45]; and the
suppressive effect of CD40L may be relevant for the development
of EBV-associated Hodgkin lymphoma [46]. It is also notable that
genital herpes simplex virus type 2 infections frequently reactivate
after the initiation of antiretroviral therapy as hallmark of the
immune reconstitution inflammatory syndrome [47,48]. The flare
of opportunistic infections may be provoked by the transient
increase of CD40L-expressing CD4+ T cells suppressing type I
interferon production. The CD40L effect may be potentiated by
the shift in the cytokine profile, namely the reduced secretion of
IFN-gamma, TNF-alpha, and IL-10, along with the enhanced
Figure 6. Effect of soluble CD40 ligand (sCD40L) on the
cytokine profile. Peripheral blood mononuclear cells (PBMC) of HIV-
infected patients (pat.) and control (ctrl.) donors were exposed to low-
dose sCD40L (50 pg/ml) for 48 hours and subsequently stimulated with
the CpG-P oligodeoxynucleotide 21798 for 20 hours. The levels of
interleukin (IL-)2, interferon gamma (IFN-g), tumor necrosis factor alpha
(TNF-a), IL-6, IL-8, and IL-10 were measured using a fluorescent bead
assay. IL-4, IL-5, IL-12, TNF-beta, and IL-1 beta were not detected. Data
are presented as mean and standard error. *p,0.05.
doi:10.1371/journal.pone.0033925.g006
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data by others reporting that CD40L is incorporated into viral
particles and induces IL-8 production in monocyte-derived
macrophages [49].
So far, the mechanism remains unclear how PDC innate
immune responses are silenced by CD40L:CD40 interactions,
which will be addressed in further studies. Beyond HIV-1
immunopathogenesis, the CD40L effect may be relevant for other
infectious diseases associated with chronic immune activation, and
autoimmune disorders. It is noteworthy that the latter can present
with CD4+ T cell lymphopenia. In this respect, interactions of
CD40 and CD40L appear to be a major factor in the
immunopathogenesis of chronic immune activation. Thus,
treatment of the immune activation without inducing further
immunosuppression appears to be a promising goal to reverse the
innate immune defect.
Supporting Information
Figure S1 Effect of immune stimulation on the expres-
sion of CD40 ligand (CD40L) on CD4+ T cell memory
subsets. After stimulation of isolated CD4+ T cells with PMA/
ionomycin for 5 h, CD40L expression was analyzed on central
memory (CM) and effector memory (EM) cells, which were
identified as CD45RO+ CCR7+ and CD45RO+ CCR72 cells,
respectively.
(TIF)
Figure S2 Impact of HIV-1 on the shedding of CD40
ligand (CD40L). Peripheral blood mononuclear cells (PBMC),
CD4+ and CD8+ T cells of five control donors were stimulated
with PHA for 3 d, and then infected without (w/o) or with (w/t)
HIV-1SF33 (MOI 0.1) for 2 d. 1610
6 cells each were exposed to
PMA/ionomycin, and soluble CD40L (sCD40L) was determined
in the cell culture supernatants at indicated time periods. Data are
presented as mean and standard error.
(TIF)
Figure S3 Longitudinal analysis of soluble CD40 ligand
(sCD40L) plasma levels in HIV-1 infected patients on
highly active antiretroviral therapy (HAART). All patients
of our study with a follow-up of at least six months on
antiretroviral therapy (n=18) were included. For the analysis,
patients were divided into two groups with more or less than 250
CD4+ T cells/ml at initiation of HAART.
(TIF)
Figure S4 Effect of HIV-1 on the induction of interferon
(IFN) alpha production. Peripheral blood mononuclear cells
(PBMC) of six control donors were preincubated with infectious or
heat-inactivated (95uC, 20 min) HIV-1SF33 at decreasing multi-
plicities of infection (MOI) for 24 hours (h) prior to stimulation
with mock or the CpG-P oligodeoxynucleotide 21798 (0.25 mM)
for additional 24 h and 48 h (data not shown). Data are presented
as mean and standard error.
(TIF)
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